Compare Mongodb Inc (MDB) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Pfizer Inc — how do they compare? Mongodb Inc trades at $370.72 (market cap $29.24B), while Pfizer Inc trades at $27.78 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 5.5× Mongodb Inc's market cap, and Pfizer Inc pays a 6.14% dividend while Mongodb Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mongodb Inc for 45 Days and Pfizer Inc for 158 Days on average.
| MDB | PFE | |
|---|---|---|
Market Cap | $29.24B | $159.59B |
Volume | 1,304,995 | 30,937,010 |
Sector | Technology | Health |
52-Week High | $472.29 | $29.02 |
52-Week Low | $225.95 | $23.67 |
Typical Hold Time | 45 Days | 158 Days |
Enterprise Value | $26.86B | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $371.35, up 2.95% today, showing strong momentum despite recent volatility. The stock faces bearish technical signals with resistance at $373, while fundamentals reveal impressive revenue growth from $1.7B to $2.0B in 2025, though net losses persist. Recent investor day highlighted AI product launches and raised long-term targets, but CEO transition creates uncertainty. Analyst consensus remains strongly bullish with $457 price target.
MDB presents a growth-at-a-price scenario with premium valuations (P/E 511) offset by strong revenue momentum and AI positioning. Near-term risks include leadership transition execution and competitive pressures, while the 80% buy rating suggests Wall Street sees 23% upside potential. Investors must weigh expensive multiples against transformative AI opportunities in database market.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
